Beneficial drugs for liver diseases

Journal of Applied Toxicology

Volumn 28, Issue 2, 2008, Pages 93-103

  Muriel, Pablo ^a   Rivera Espinoza, Yadira ^b  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Colchicine; Curcumin; Interferons; Liver damage; Nitric oxide; Resveratrol; S adenosyl L methionine; Silymarin; Thalidomide

Indexed keywords

ALPHA2A INTERFERON; CARBON TETRACHLORIDE; COLCHICINE; CORTICOSTEROID; CURCUMIN; DEACETYLCOLCHICINE; GLYCYRRHIZIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERFERON ALPHA2B; LIV 52; MZ 80; NITRIC OXIDE; PARACETAMOL; PEGYLATED INTERFERON ALPHA2B; RESVERATROL; RIBAVIRIN; S ADENOSYLMETHIONINE; SILYMARIN; STEROID; THALIDOMIDE; THIOACETAMIDE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AGITATION; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ANGIOGENESIS; ANXIETY; AUTOIMMUNE DISEASE; BEHCET DISEASE; BIRTH DEFECT; CHOLESTASIS; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DISCOID LUPUS ERYTHEMATOSUS; DOWN REGULATION; DRUG ABSORPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; ENZYME ACTIVITY; ERYTHEMA NODOSUM LEPROSUM; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; GOUT; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LEPROSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER PROTECTION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METHYLATION; MUSHROOM POISONING; NEOPLASM; NEPHROTIC SYNDROME; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PRURIGONODULARIS; RETINA ISCHEMIA; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN DISEASE; SUICIDAL IDEATION; SUICIDE; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS; VISUAL ACUITY;

ADRENAL CORTEX HORMONES; ANIMALS; COLCHICINE; CURCUMIN; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; GLYCYRRHIZIC ACID; HUMANS; INTERFERONS; LIVER DISEASES; NITRIC OXIDE; PLANT EXTRACTS; S-ADENOSYLMETHIONINE; SILYMARIN; STILBENES; THALIDOMIDE;

ANIMALIA;

EID: 41149155974     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1310     Document Type: Review

References (135)

1. Abe N, Ebina T, Ishida N. 1982. Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice. Microbiol. Immunol. 26: 535-539.
2. Abe Y, Hashimoto S, Horie T. 1999. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol. Res. 39: 41-47.
3. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishoda S, Takada Y. 2004. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 24: 2783-2840.
4. Aggarwal BB, Bhatt ID, Ichikawa H, Ahn KS, Sethi G, Sandur SK, Natarajan C, Seeram N, Shishodia S. 2007. Curcumin: biological and medicinal properties. In Turmeric: The Genus Curcuma, Ravindran PN, Nirmal-Babu K, Sivaraman K (eds). Series: Medicinal and Aromatic Plants - Industrial Profiles Volume 45. CRC Press: New York; 297-368.
5. Ammon HP, Walh MA. 1991. Pharmacology of Curcuma longa. Planta Med. 57: 1-7.
6. Ara C, Kirimlioglu H, Karabulut AB, Coban S, Ay S, Harputluoglu M, Kirimlioglu V, Yilmaz S. 2005. Protective effect of resveratrol against oxidative stress in cholestasis. J. Surg. Res. 127: 112-117.
7. Baker DE. 2003. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. Rev. Gastroenterol. Disord. 3: 93-109.
8. Bruck R, Ashkenazi M, Weiss S, Goldiner I, Shapiro H, Aeed H, Genina O, Helpern Z, Pines M. 2007. Prevention of liver cirrhosis in rats by curcumin. Liver Int. 27: 373-383.
9. Castro V, Muriel P. 1996. Comparative study of colchicine and trimethylcolchicinic acid on prolonged bile duct obstruction in the rat. J. Appl. Toxicol. 16: 269-275.
10. 4-induced cirrhosis in the rat. Pharmacol. Toxicol. 79: 241-246.
11. 4 treatment in rats. J. Appl. Toxicol. 27 (in press). DOI: 10.1002/jat.1249
12. Chong LW, Hsu YC, Chiu YT, Yang KC, Huang YT. 2006. Antifibrotic effects of thalidomide on hepatic stellate cells and dimethylnitrosamine-intoxicated rats. J. Biomed. Sci. 13: 403-418.
13. Chuah B, Lim R, Boyer M, Ong AB, Wong SW, Kong HL, Millward M, Clarke S, Goh BC. 2007. Multi-centre phase II trial of thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol. 46: 234-238.
14. Czaja MJ, Weiner FR, Takahashi S, Giambrone MA, Van Der Meide PH, Schellekens H, Bienpica L, Zern MA. 1989. γ-Interferon treatment inhibits collagen deposition in muriene schistosomiasis. Hepatology 10: 795-800.
15. Desplaces A, Choppin J, Vogel G. 1975. The effects of silymarin on experimental phalloidine poisoning. Arzneimittelforschung 25: 89-96.
16. Dhiman RK, Chawla YK. 2005. Herbal medicines for liver diseases. Dig. Dis. Sci. 10: 1807-1812.
17. Dong Z. 2003. Molecular mechanisms of the chemopreventive effect of resveratrol. Mutat. Res. 523: 145-150.
18. Fauconneau B, Waffo-Teguo P, Huguet F, Barrier L, Decendit A, Merillon JM. 1997. Comparative study of radical scavenger and anti-oxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sci. 61: 2103-2110.
19. Fernandez-Martínez E, Morales-Ríos MS, Pérez- Álvarez V, Muriel P. 2001. Effects of thalidomide and 3-phthalimido-3-(3,4-dimethoxyphenyl)-propanamide on bile duct obstruction-induced cirrhosis in the rat. Drug Dev. Res. 54: 209-218.
20. Fernández-Martínez E, Morales-Ríos MS, Pérez-Álvarez V, Muriel P. 2004. Immunomodulatory effects of thalidomide analogs on LPS-induced plasma and hepatic cytokines in the rat. Biochem. Pharmacol. 68: 1321-1329.
21. Flohé L, Draeger E, Frankus E, Gradums I, Günsler WA, Helm FC, Kuutti-Savolainen ER. 1981. Studies on the hypothetical relationship of thalidomide-induced embryopathy and collagen biosynthesis. Arzneimittelforsch. 31: 315-320.
22. Flora K, Hahn M, Rosen H, Benner K. 1998. Milk thistle (Silybum marianum) for the therapy of liver disease. J. Gastroenterol. 93: 139-143.
23. Fremont L. 2000. Biological effects of resveratrol. Life Sci. 66: 663-673.
24. Giannelli G, Bergamini C, Marinosci F, Fransvea E, Napoli N, Maurel P, Antonaci S. 2006. Antifibrogenic effect of IFN-alpha2b on hepatic stellate cell activation by human hepatocytes. J. Interferon Cytokine Res. 26: 301-308.
25. Giri SN, Hyde MD. 1986. Ameliorating effect of murine interferon gamma on bleomycin-induced lung collagen fibrosis in mice. Biochem. Med. Metab. Biol. 36: 194-197.
26. Goldring MB, Sandell LJ, Stephenson ML, Krane SM. 1986. Immune interferon suppresses levels of procollagen mRNA and type II collagen synthesis in cultured human articular and costal chondrocytes. J. Biol. Chem. 261: 9049-9056.
27. Granstein RD, Murphy GF, Margolis RJ. 1987. Gamma-interferon inhibits collagen synthesis in the mouse. J. Clin. Invest. 79: 1254-1258.
28. Guido M, De Franceschi L, Olivari N, Leandro G, Felder M, Corrocher R, Rugge M, Pasino M, Lanza C, Capelli P, Fattovich G. 2006. Effects of interferon plus ribavirin treatment on NF-kappaB, TGF-betal, and metalloproteinase activity in chronic hepatitis C. Mod. Pathol. 19: 1047-1054.
29. Huang MT, Wei M, Lu YP, Chang RL, Fisher C, Manchand PS, Newmark HL, Conney AH. 1995. Effects of curcumin, demethoxy-curcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion. Carcinogenesis 16: 2493-2497.
30. Huseini HF, Alavian SM, Heshmat R, Heydari MR, Abolmaali K. 2005. The efficacy of Liv-52 on liver cirrhotic patients: a randomized double-blind, placebo-controlled first approach. Phytomedicine 12: 619-624.
31. Inagaki Y, Nemoto T, Kushida M, Sheng Y, Higashi K, Ikeda K, Kawada N, Shirasaki F, Takehara K, Sugiyama K, Fuji M, Yamauchi H, Nakao A, de Crombrugghe B, Watanabe T, Okazaki I. 2003. Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 38: 890-899.
32. Ireson C, Orr S, Jones DJ, Verchoyle R, Lim CK, Luo JL, Howells L, Plummer R, Jukes M, Williams M, Steward WP, Gescher A. 2001. Characterization of metabolites of the chemopreventive agent cur-cumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 61: 1058-1064.
33. Jin L, Caldwell RB, Li-Masters T, Caldwell RW. 2007. Homocysteine induces endothelial dysfunction via inhibition of arginine transport. J. Physiol. Pharmacol. 58: 191-206.
34. Kasdallah-Grissa A, Mornagui B, Aouani E, Hammami M, Gharbi N, Kamoun A, El-Fazaa S. 2006. Protective effect of resveratrol in rats. Alcohol Alcohol 41: 236-239.
35. Kawada N, Seki S, Inoue M, Kuroki T. 1998. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 27: 1265-1274.
36. Kershenobich D, Vargas F, Garcia-Tsao G, Perez Tamayo R, Gent M, Rojkind M. 1988. Colchicine in the treatment of the liver. N. Engl. J. Med. 318: 1709-1713.
37. Kinsell LW, Harper HA, Barton HC, Hutchin ME, Hess JR. 1948. Studies in methionine and sulfur metabolism. I. The fate of intravenously administered methionine, in normal individuals and in patients with liver damage. J. Clin. Invest. 27: 677-688.
38. Kropacova K, Misurova E, Hakova H. 1998. Protective and therapeutic effect of silymarin on the development of latent liver damage. Radiat. Biol. Radioecol. 38: 411-415.
39. Li M, Zhang Z, Hill DL, Wang H, Zhang R. 2007. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the P13K/mTOR/ETS2 pathway. Cancer Res. 67: 1988-1996.
40. Liu JY, Lin SJ, Lin JK. 1993. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 14: 857-861.
41. Lucena MI, Andrade RJ, de la Cruz JP, Rodriguez-Mendizabal M, Blanco E, Sánchez de la Cuesta F. 2002. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. Int. J. Clin. Pharmacol. Ther. 40: 2-8.
42. Ludford RJ. 1945. Colchicine in the experimental chemotherapy of cancer. J. Natl Cancer Inst. 6: 89-101.
43. Luper S. 1998. A review of plants used in the treatment of liver disease: Part 1. Altern. Med. Rev. 3: 410-421.
44. Maheswari RK, Singh AK, Gaddipati J, Srimal RC. 2006. Multiple biological activities of curcumin: A short review. Life Sci. 78: 2081-2087.
45. Malawista SE. 1968. Colchicine: a common mechanism for its anti-inflammatory and anti-mitotic effects. Arthritis Rheum. 11: 191-198.
46. Marchand YL, Singh A. 1973. A role for the microtubular system in the release of very low density lipoproteins by perfused mouse livers. J. Biol. Chem. 218: 6862-6870.
47. Marriot JB, Müller G, Dalgleish AG. 1999. Thalidomide as an emerging immunotherapeutic agent. Immunol. Today 20: 538-540.
48. Mathew TC, Abdeen S, Dashti H, Mafhew E, Al-Bader A. 2007. Effect of alpha-interferon and alpha-tocopherol in reversing hepatic cirrhosis in rats. Anat. Histol. Embryol. 36: 88-93.
49. Mathurin P, Mendenhall CL, Carithers RL Jr, Ramond MJ, Maddrey WC, Garstide P, Rueff B, Naveau S, Chaput JC, Poynard T. 2002. Corticosteroids improve short term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe alcoholic hepatitis. J. Hepatol. 36: 480-487.
50. Mato JM, Alvarez L, Ortiz P, Pajares MA. 1997. S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol. Ther. 73: 265-280.
51. Mato JM, Cámara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, García-Buey L, Benita V, Caballeria J, Sola R, Moreno-Otero R, Barrao F, Martín-Duce A, Correa JA, Pares A, Barrao E, García-Magaz I, Puerta JL, Moreno J, Boissard G, Ortiz P, Rodes J. 1999. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J. Hepatol. 30: 1081-1089.
52. Mato JM, Corrales FJ, Lu SC, Avila MA. 2002. S-adenosylmethionine: a control switch that regulates liver function. FASEB J. 16: 15-26.
53. Mato JM, Lu SC. 2007. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology 45: 1307-1312.
54. Miller AL. 1996. Antioxidant flavonoids: structure, function and clinical usage. Altern. Med. Rev. 1: 103-111.
55. Miller MT, Strömland K. 1999. Teratogen update: thalidomide, a review, with focus on ocular findings and new potential uses. Teratology 60: 306-321.
56. Miyaji C, Miyakawa R, Watanabe H, Kawamura H, Abo T. 2002. Mechanisms underlying the activation of cytotoxic function mediated by hepatic lymphocytes following the administration of glycyrrhizin. Int. Immunopharmacol. 2: 1079-1086.
57. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. 1993. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 177: 1675-1680.
58. 2b,. Biochem. Pharmacol. 50: 515-520.
59. 4 in mice. J. Appl. Toxicol. 26: 326-332.
60. Mourelle M, Meza MA. 1989. Colchicine prevents D-galactosamine- induced hepatitis. J. Hepatol. 8: 165-172.
61. 4 induced liver cirrhosis by silymarin. Fund. Clin. Pharmacol. 3: 183-191.
62. Muir AJ, Sylvestre PB, Rockey DC. 2006. Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. J. Viral Hepatol. 13: 322-328.
63. Mukai T, Nagaki M, Imose M, Kimura K, Satake S, Moriwaki H. 2006. Prevention of hepatic fibrosis in nonobese diabetic mice: critical role for interferon-γ. Liver Int. 26: 1006-1014.
64. Mukherjee S, Lyden E. 2006. Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series. Liver Int. 26: 529-535.
65. Müller GW, Shire MG, Wong LM, Corral LG, Patterson RT, Chen Y, Stirling D. 1996. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J. Med. Chem. 39: 3238-3240.
66. Muriel P. 1993. S-adenosyl-L-methionine prevents and reverses erythrocyte membrane alterations in cirrhosis. J. Appl. Toxicol. 13: 179-182.
67. Muriel P. 1995. Interferon-α preserves erythrocyte and hepatocyte ATPase activities from liver damage induced by prolonged bile duct ligation in the rat. J. Appl. Toxicol. 15: 449-453.
68. Muriel P. 1998. Nitric oxide protection of rat liver from lipid peroxidation, collagen accumulation, and liver damage induced by carbon tetrachloride. Biochem. Pharmacol. 56: 773-779.
69. 21,. Drug Dev. Res. 48: 45-52.
70. Muriel P. 2000. Regulation of nitric oxide synthesis in the liver. J. Appl. Toxicol. 20: 189-195.
71. Muriel P. 2006. Role of nitric oxide in liver disorders, In Liver Diseases: Biochemical Mechanisms and New Therapeutic Insights, Ali S, Friedman SL, Mann DA (eds). Science Publishers: Enfield (NH) Jersey; 115-131.
72. Muriel P. 2007a. Cytokines in liver diseases. In Hepatotoxicity: From Genomics to In Vitro and In Vivo Models, Sahu S (ed.). John Wiley & Sons: Chichester (in press).
73. Muriel P. 2007b. Some experimental models of liver damage. In Hepatotoxicity: from Genomics to In Vitro and In Vivo Models, Sahu S (ed.). John Wiley & Sons: Chichester (in press).
74. Muriel P, Bolaños J, Barrai JM, Torres G. 1994a. Effect of alpha-interferon on erythrocyte and hepatocyte plasma membranes derived from cirrhotic rats. Pharmacology 48: 63-68.
75. 2b on liver fibrosis and cholestasis induced by biliary obstruction in rats. Pharmacology 54: 179-185.
76. 2b, on liver damage induced by bile duct ligation in rats. J. Appl. Toxicol. 18: 143-147.
77. 4-cirrhosis in the rat. Eur. J. Hepatol. Gastroenterol. 15: 951-957.
78. Muriel P, Garciapiña T, Perez-Alvarez V, Mourelle M. 1992. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J. Appl. Toxicol. 12: 439-442.
79. Muriel P, Gonzalez P. 1998. Liver damage induced by acute cholestasis in the rat is ameliorated partially by L-arginine. Comp. Biochem. Physiol. (Part C) 120: 421-424.
80. 4 administration in the rat after discontinuation of treatment: Effect of silymarin, silibinin, colchicine and trimethylcolchicinic acid. Basic Clin. Pharmacol. Toxicol. 96: 375-380.
81. Muriel P, Mourelle M. 1990a. Prevention by silymarin of membrane alterations in acute liver damage. J. Appl. Toxicol. 10: 275-279.
82. Muriel P, Mourelle M. 1990b. The role of membrane composition in ATPases activities of cirrhotic rats. Effect of silymarin. J. Appl. Toxicol. 10: 281-284.
83. Muriel P, Mourelle M. 1992. Characterization of membrane fraction lipid composition and function of cirrhotic rat liver. Role of S-adenosyl-L- methionine. J. Hepatol. 14: 16-21.
84. Muriel P, Quintanar ME, Pérez-Alvarez V. 1993. Effect of colchicine on acetaminophen-induced liver damage. Liver 13: 217-221.
85. Muriel P, Suarez OR, Gonzalez P, Zuniga L. 1994b. Protective effect of S-adenosyl-L-methionine on liver damage induced by biliary obstruction in rats: a histological, ultrastructural and biochemical approach. J. Hepatol. 21: 95-102.
86. Nakamura Y, Ohto Y, Murakami A, Osawa T, Ohigashi H. 1998. Inhibitory effects of curcumin and tetrahydrocurcuminoids on the tumor promoter-induced reactive oxygen species generation in leukocytes in vitro and in vivo. Jpn J. Cancer Res. 89: 361-370.
87. Okada K, Wangpoengtrakul C, Tanaka T, Toyokuni S, Uchida K, Osawa T. 2001. Curcumin and especially tetrahydrocurcumin ameliorate oxidative stress-induced renal injury in mice. J. Nutr. 131: 2090-2095.
88. Palmer RM, Ferrige AG, Moncada S. 1987. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524-526.
89. Pari L, Amali DR. 2005. Protective role of tetrahydrocurcumin (THC) an active principle of tumeric on chloroquine induced hepatotoxicity in rats. J. Pharm. Pharm. Sci. 8: 115-123.
90. Pari L, Murugan P. 2004. Protective role of tetrahydrocurcumin against erythromycin estolate-induced hepatotoxicity. Pharmacol. Res. 49: 481-486.
91. Pascale RM, Simile MM, De Miglio MR, Feo F. 2002. Chemoprevention of hepatocarcinogenesis: S-adenosyl-L-methionine. Alcohol 27: 193-198.
92. Pascual C, González R, Armesto J, Muriel P. 1993. Effect of silymarin and silybinin on oxygen radicals. Drug Develop. Res. 29: 73-77.
93. Pendurthi UR, Williams JT, Rao LV. 1999. Resveratrol, a polyphenols compound found in wine, inhibits tissue factor expression in vascular cells: a possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. Arterioscler. Thromb. Vasc. Biol. 19: 419-426.
94. Pinzanie M, Marra F. Carloni V. 1998. Signal transduction in hepatic stellate cells. Liver 18: 2-13.
95. Pradhan SC, Girish C. 2006. Hepatoprotective herbal drug silymarin from experimental pharmacology to clinical medicine. Indian J. Med. Res. 124: 491-504.
96. Raje N, Anderson K. 1999. Thalidomide: a revival story. N. Engl. J. Med. 341: 1606-1608.
97. Rambaldi A, Gluud C. 2001a. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst. Rev. 3: CD002148.
98. Rambaldi A, Gluud C. 2001b. S-adenosyl-L-methionine for alcoholic liver disease. Cochrane Database Syst. Rev. 4: CD002235.
99. Rambaldi A, Iaquinto G, Gluud C. 2002. Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane review. Am. J. Gastroenterol. 97: 1674-1681.
100. Rao CV, Rivenson A, Simi B, Reddy BS. 1995. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 55: 259-266.
101. Ravindranath V, Chandrasekhara N. 1982. Metabolism of curcumin - studies with [3H] curcumin. Toxicology 22: 337-344.
102. Reyes-Gordillo K, Segovia J, Shibayama M, Vergara P, Moreno MG, Muriel P. 2007. Curcumin protects against acute liver damage in the rat by inhibiting NF- κB, proinflammatory cytokines production and oxidative stress. Biochim. Biophys. Acta 1770: 989-996.
103. Rincon D, Ripoll C, Catalina MV, Salcedo M, Banares R. 2006. Does interferon improve portal hypertension? J. Antlmicrob. Chemother. 58: 7-12.
104. 4 in the rat. J. Appl. Toxicol. (in press). DOI: 10.1002/jat/1260
105. 2b increases fibrolysis in fibrotic livers from bile duct ligated rats. Possible participation of the plasminogen activator. Pharmacology 51: 341-346.
106. Roy A, Soni GR, Kolhapure RM, Karnik UR, Patki PS. 1994. Down regulation of tumor necrosis factor activity in experimental hepatitis by a herbal formulation, Liv 52. Indian J. Exp. Biol. 32: 694-697.
107. Saller R, Meier R, Brignoli R. 2001. The use of silymarin in the treatment of liver diseases. Drugs 61: 2035-2063.
108. Salmi HA, Sarna S. 1982. Effects of silymarin on chemical, functional and morphological alterations of the liver. A double-blind controlled study. Scand. J. Gastroenterol. 17: 517-521.
109. Sandhir R, Gill KD. 1999. Hepatoprotective effects of Liv 52 on ethanol induced liver damage in rats. Indian J. Exp. Biol. 37: 762-766.
110. Seef LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. 2001. Complementary and alternative medicine in chronic liver disease. Hepatology 34: 595-603.
111. Sener G, Toklu HZ, Sehirli O, Velioglu-Ogunc A, Cetinel S, Gedic N. 2006. Protective effects of resveratrol against acetaminophen-induced toxicity in mice. Hepatol. Res. 35: 62-68.
112. Shiki Y, Shinai K, Satto Y, Yoshida S, Mosi Y, Wakashin M. 1992. Effect of glycyrrhizin on lysis of hepatocyte membranes induced by anti-liver cell membrane antibody. J. Gastroenterol. Hepatol. 7: 12-16.
113. Simin M, Brok J, Stimac D, Gluud C, Gluud LL. 2007. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment. Pharmacol. Ther. 25: 1153-1162.
114. Singh S, Aggarwal BB. 1995. Activation of transcription factor NF-κB is suppressed by curcumin (dyferulolylmethane). J. Biol. Chem. 270: 24995-25000.
115. Soriano V, Labarga P, Ruiz-Sancho A, Garcia-Samaniego J, Barreiro P. 2006. Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin. AIDS 20: 2225-2227.
116. Spahr L, Rubbia-Brandt L, Pugin J, Giostra E, Frossard JL, Borisch B, Hadengue A. 2001. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. J. Hepatol. 35: 582-589.
117. Srivastava S, Srivastava AK, Patnaik GK, Dhawan BN. 1994. Effect of picroliv and silymarin on liver regeneration in rats. Indian J. Pharmacol. 26: 19-22.
118. Stephenson ML, Krane SM, Amento EP, McCroskery PA, Byrne M. 1985. Immune interferon inhibits collagen synthesis by rheumatoid synovial cells associated with decreased levels of procollagen mRNAs. FEBS Lett 180: 43-50.
119. Tabata C, Tabata R, Kadokawa Y, Hisamori S, Takahashi M, Mishima M, Nakano T, Kubo H. 2007. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J. Immunol. 179: 708-714.
120. Tan J, Lok AS. 2007. Update on viral hepatitis: 2006. Curr. Opin. Gastroenterol. 23: 263-267.
121. Tanaka T, Makita H, Ohnishi M, Hirose Y, Wang A, Mori H, Satoh K, Hara A, Ogawa H. 1994. Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by dietary curcumin and hesperidin: comparison with the protective effect of β-carotene. Cancer Res. 54: 4653-4659.
122. Tasci I, Mas MR, Vural SA, Deveci S, Comert B, Alcigir G, Mas N, Akay C, Bozdayi M, Yurdaydin C, Bozkaya H, Uzunalimoglu O, Isik AT, Said HM. 2007. Pegylated interferon-alpha plus taurine in treatment of rat liver fibrosis. World J. Gastroenterol. 13: 3227-3244.
123. Thakur SK. 2002. A hepatoprotective agent. Gastroenterol Today 6: 78-82.
124. Tsai SH, Lin-Shiau SY, Lin JK. 1999. Suppression of nitric oxide synthase and the down regulation of the activation of NF kappa B in macrophages by resveratrol. Br. J. Pharmacol. 126: 673-680.
125. Tsukamoto HC, Lu SC. 2001. Current concepts in the pathogenesis of alcoholic liver injury. FASEB J. 15: 1335-1349.
126. Wadsworth TL, Koop DR. 1999. Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages. Biochem. Pharmacol. 57: 941-949.
127. Walle T, Hsieh F, Delegge MH, Oatis JE Jr, Walle K. 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dis. 32: 1377-1382.
128. Wang M, Grange LL, Tao J. 1996. Hepatoprotective properties of Silybum marianum herbal preparation on ethanol-induced liver damage. Fitoterapia 67: 167-171.
129. Weber LW, Boll M, Stampfl A. 2003. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol. 33: 105-136.
130. Wu CG, Chamuleau RA, Bosch KS. 1993. Protective effect of silymarin on rat liver injury induced by ischemia. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 64: 259-263.
131. Yeh WS, Armstrong EP, Skrepnek GH, Malone DC. 2007. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the veterans affairs health care system. Pharmacotherapy 27: 813-824.
132. Yoshiji H, Noguchi R, Kojima H, Ikenaka Y, Kitade M, Kaji K, Uemura M, Yamao J, Fujimoto M, Yamazaki M, Toyohara M, Mitoro A, Fukui H. 2006. Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C. World J. Gastroenterol. 12: 6786-6791.
133. Yoshikawa M, Matsui Y, Kawamoto H, Umemoto N, Oku K, Koizumi M, Yamao J, Kuriyama S, Nakano H, Hozumi N, Ishizaka S, Fukui H. 1997. Effects of glycyrrhizin on immune mediated cytotoxicity. J. Gastroenterol. Hepatol. 12: 243-248.
134. Zhang FK, Zhang JY, Jia JD. 2005. Treatment of patients with alcoholic liver disease. Hepatobiliary Pancreat. Dis. Int. 4: 12-17
135. Zweig MH, Chignell CF. 1973. Interactions of some colchicine analogs, vinblastine and podophyllotoxin with rat brain microtubule protein. Biochem. Pharmacol. 22: 2141-2150